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A B S T R A C T
Solobacterium moorei (S. moorei) has been described as Gram-positive, non spore forming, obligate anaerobic
bacillus from human feces. The traditional culture and identification of these strains is very difficult (as the strains
are often not cultivable or they grow only relatively slowly, in addition to producing only a very few positive bio-
chemical reactions in commercially available identification kits); thus, reliable identification may only be carried
out using methods, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and DNA
sequencing. Regarding its pathogenic role, the relevance of S. moorei in halitosis (oral malodor) has a good stand-
ing, as it has been suggested by multiple studies, while the isolation of these bacteria from invasive infections
is very rare; there are only a few reports available in the literature, regarding infections outside the oral cavity.
Based on these reports, affected patients are predominantly characterized compromised immunity and are fre-
quently associated with a dental focus of infection. The aim of our present review is to summarize the currently
available knowledge on the pathogenic role of S. moorei in halitosis and other infections and to emphasize the
relevance of this neglected anaerobic pathogen.
1. Introduction, halitosis as a clinical problem
Halitosis (foetor oris, foetor ex ore, colloquially: foul breath, oral
malodour) is the medical term used to describe all of the unpleasant
smells and odors from the expired air, mouth or from outside the oral
cavity, without any information about the correct source [1]. Approx-
imately 10–30% of the adults in US and in the European Union and
30–60% of adults in developing countries suffer from this type of oral
malodor [2]. Halitosis may occur under physiological conditions, such
as nocturnal hyposalivation, however, this may be amended by proper
oral hygiene [3]. Other causes (especially for transient malodor) with-
out any pathological conditions include smoking, mastication of differ-
ent parts of vegetables and consumption of various spices (e.g., onion
or garlic) and alcohol [4, 5, 6, 7]. Hyposalivation/xerostomia (due
to Sjögren's syndrome, adverse events associated with anticholinergic
drugs, centrally-acting psychoactive agents, chemotherapy and radiation
therapy) is also a very common cause of halitosis [8, 9, 10]. Some pa-
tients may suffer from halitophobia, a condition during which the af-
fected person constantly fears that the smell of their oral region is re
garded as repulsive by other people [8]. When assessing the origins
of halitosis, most cases are found to originate from the oral cavity
(80–90%; intra-oral halitosis: IOH, including infections or abscesses in
the oral cavity, deep carious lesions, periodontal diseases, pericoroni-
tis), while remaining cases are corresponding to non-oral causes (ex-
tra-oral halitosis: EOH) [11]. Based on the classification of Aydin and
Harvey-Woodworth, the revised classification of halitosis includes phys-
iological (Type 0) and pathological Type 1–5 (1: oral, 2: airway, 3: gas-
tro-esophageal, 4: blood-borne, 5: objective) halitosis [12]. Ingestion of
some chemical compounds may also cause halitosis – if the metabolic
end-products of these agents are stable in blood, or they are capable of
increasing the pH locally – facilitating the growth of halitosis-causing
bacteria in the oral cavity [13, 14, 15, 16, 17]. Gastro-esophageal re-
flux disease (GERD) is also an important cause of malodor, with a sim-
ilar underlying mechanism (increasing the pH in the oral cavity) [18].
The presence and overgrowth of many microorganisms has been impli-
cated in causing oral malodor; with the advent of novel microbiological
and diagnostic technologies, novel microbial species have also been as-
sociated with halitosis [19]. Although the literature regarding the topic
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is scarce, one of the novel species suggested to contribute to halito-
sis is Solobacterium moorei (S. moorei) [20]. In the present review, we
aimed to surmise the the currently available knowledge on this ne-
glected anaerobic pathogen – regarding its role in halitosis, in addition
to the relevance of these bacteria in other, invasive human infections –
to increase its notoriety among clinicians, dentists and clinical microbi-
ologists.
2. Microbiology of Solobacterium moorei
S. moorei has been described as Gram-positive, non-spore-forming,
obligate anaerobic bacillus from human feces by Kageyama and Benno
in 2000, currently being the only member of the Solobacterium genus
[21]. The bacterium was considered first as a native member of the
human intestinal microbiome, but later, their pathogenic role has been
identified in halitosis [22]. At the time of their discovery, phyloge-
netic analysis disclosed that the isolated strains were members of the
Clostridium subphylum of Gram-positive bacteria [21]. The name of
this species was originally known as Bulleida extructa or B. moorei; the
genus Bulleida is a member of the Erysipelotrichidae family, which shows
pronounced differences from the other genera of non-spore-forming
Gram-positive bacilli, e.g., Bifidobacterium, Cutibacterium and Lactobacil-
lus [23]. According to the original investigation, the tested S. moorei
strains showed a 93% sequence similarity only to B. extructa, in addi-
tion to other phenotypic differences, therefore, a brand new genus was
created [24]. Based on 16S rRNA gene sequencing data, S. moorei only
has around 86% sequence homogeneity to Erysipelothrix rhusiopathiae
and 87% to Holdemania filiformis, other representative members of the
Erysipelotrichidae family [25]. The first deposited type strain of Solobac-
terium moorei is JCM 10645T [6]. Phenotypically, these rods are 0.2 μm
by 0.4–0.7 μm in size and they do not possess flagella [1]. The tra-
ditional culture and identification of these strains is very difficult, as
the strains are often not cultivable or they grow only relatively slowly,
in addition to producing only a very few positive biochemical reac-
tions in commercially available identification kits [21, 26]. The tradi-
tional phenotypic biochemical tests (as shown in the literature) are not
adequate for the identification of these bacteria, due to the phenom-
enon of wide variety of phenotypic presentation, i.e. the isolates are
not able to produce an uniform amount of positive and negative reac-
tions to be reliably identified by biochemical methods [21, 22, 26].
Most of the published clinical S. moorei isolates characterized ferment
glucose, galactose, fructose, maltose and ribose and hydrolyse esculine
[21, 22, 26, 27]. The main product from glucose fermentation is acetic
acid, while the other non-spore-forming anaerobic bacteria (e.g., Bifi-
dobacterium, Cutibacterium, Eubacterium and Lactobacillus) may produce
propionic acid, lactic acid, acetic acid, butyric acid and formic acid
[28]. Zheng et al. reported that by using Rapid ID 32A test (bioMérieux,
Marcy-l’Étoile, France), the investigated S. moorei clinical strains were
show to produce α- and β-galactosidase (which play important roles
in halitosis), α-glucosidase, arginine dihydrolase, arginine arylamidase,
leucine arylamidase, proline arylamidase, alkaline phosphatase enzymes
[24]. In a similar experiment, nitrate reduction, esterase and valine ary-
lamidase production was also shown by the type strain JCM 10645T
by the API ZYM system (bioMérieux, Marcy-l’Étoile, France) [24]. Af-
ter 48–72 h of strict anaerobic cultivation, S. moorei forms small, grey
colonies with a 0.5–1 mm diameter, some strains were described as
α-haemolytic on anaerobic blood agar [24], although the isolate pub-
lished by Lau et al. was non-haemolytic [27]. S. moorei strains have the
ability to adhere to the lipophilic surface molecules of the oral epithelial
cells through adhesins of hydrophobic character [29]. In addition, they
may produce biofilms in the oral cavity; this biofilm-formation may be
the first key step in the ecological succession in the mouth, leading to
the development of halitosis [30].
Due to these hindrances, i.e. obscurity of the pathogen, difficul-
ties in the isolation and correct species-level identification of S. moorei
strains (especially in mixed cultures), there is a considerable underes-
timation of the real clinical significance of these bacteria in clinical
situations [31]. The amount of publications concerning S. moorei are
still scarce, nevertheless, the reported cases involving S. moorei infec-
tions increased significantly in recent years [21, 24, 27, 32, 33, 34,
35, 36, 37]. Nowadays, there has been considerable development and
technological advancements in the methods used by routine clinical
microbiology laboratories. Molecular diagnostic methods, such as ma-
trix-assisted laser desorption/ionization time-of-flight mass spectrome-
try (MALDI-TOF) and DNA sequencing methods are essential for finding
and appropriately identifying these bacteria from human clinical speci-
mens [21, 22, 24, 38, 39, 40]. A summarizing table on the relevance of
various microbiological techniques in the identification and diagnosis of
S. moorei is presented in Table 1.
3. Role of S. moorei halitosis
The presence of anaerobic bacteria in clinical specimens can easily
be distinguished owing to their putrescent smell [41]. This smell is due
to the anaerobic respiration of these bacteria and the production of in-
dole, skatole, polyamines, volatile sulfur compounds (VSCs; such as hy-
drogen sulfide, dimethyl sulfide, methyl mercaptan and allyl methyl sul-
fide), organic acids (e.g. amines such as cadaverine and putrescin; acetic
acid and propionic acid) and short-chain fatty acids (SCFAs; including
isovaleric and isobutyric acid) [42, 43]. The dorsum of the tongue pro-
vides a suitable environment for the accumulation of bacteria associ-
ated with halitosis, as the oxygen levels in the deep crypts of the tongue
tend to be very low [44]. Species of the genera Bacteroides, Centipeda,
Eikenella, Fusobacterium, Porphyromonas, Prevotella, Tannerella and Tre-
ponema have been highlighted as potent producers of the main VSCs
and related compounds implicated in halitosis [45]. In addition, most
of the abovementioned bacteria has been described as important peri-
odonto-pathogenic species [46]. Out of the VSCs, S. moorei is capable to
converting cysteine into hydrogen sulfide; in contrast –based on the re-
sults of Tanabe et al. and de Lima et al. – these bacteria are unable to
produce methyl mercaptan from methionine or to produce other VSCs
from complex proteins [47, 48]. The enzyme responsible (and the gene
encoding for this enzyme) has been identified as the cysteine desulfhy-
drase, catalyzing the breakdown of cysteine into hydrogen sulfide, am-
monia and pyruvate [47]. In addition, they have noted that S. moorei
can only produce VSCs from mucin in the presence of an exogenous pro-
tease (e.g., Arg-gingipain produced by P. gingivalis) [48]. Nevertheless,
as the dorsal region of the tongue is a rich source of proteases, VSC-pro-
duction may in fact be important for S. moorei in vivo [49]. This might
explain why there were higher levels of S. moorei found in the tongue
coatings and saliva of patients with halitosis [50]. Due to its β-galactosi-
dase-activity, S. moorei can also produce VSCs from salivary glycopro-
teins; this is relevant, considering that increased β-galactosidase-activity
in the saliva has been associated with oral malodor [51, 52].
There is evidence to suggest that even very low concentrations of
VSCs may be toxic [53, 54]. The toxicity may be related to the mech-
anisms of action of the agents that comprise VSCs; e.g., hydrogen sul-
fide can split protein disulfide bonds to form persulfide groups, bind
essential metal ions and may inhibits enzymes such as myeloperoxi-
dase, catalase, carbonic anhydrase and Na+/K+ ATP-ase, thus potenti-
ating the mutagenicity of hydrogen peroxide [53, 54]. Another source
of VSCs for example methyl mercaptan, increases the permeability of
intact oral mucosa and stimulates cytokine production, leading to in-
flammation; for example, VSCs may induce the secretion of IL-8, which
will subsequently induce osteoclast differentiation and contribute to the
development of periodontitis [55, 56, 57]. Increased VSCs levels even
may play a potential role in the link between oral infection and sys-
temic diseases, such as preterm low birth weight and cardiovascular
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Table 1
Relevance of various microbiological techniques in the identification and diagnosis of S. moorei.
Method Description Characteristics Producer Advantage Disadvantage
Conventional
methods
Gram stain, wet
mount
characteristics,
and susceptibility
to metronidazole,
vancomycin,
kanamycin,
colistin, and bile
Obligately anaerobic, Gram-positive, non-
motile, nonsporing rod,
Cell size: 0.2 μm x 0.4–0.7 μm
- Essential as a
basic test
The strains grow slowly and phenotypic
variations appear to be commonly
exhibited by different strains.
Gas-liquid
chromatography
(GLC)
Differentiation is
based on
fermentation
products from
glucose
Moderate amounts of acetic, lactic, and
butyric acids and some strains also produced
a small amount of pyruvic acid from PYFG
broth.
- None,
outdated
method.
-
Fermentation of
carbohydrates
and enzyme
tests
Acid production from ribose, glucose,
galactose, fructose, and maltose
No acid production from arabinose, xylose,
rhamnose, mannose, sucrose, cellobiose,
lactose, trehalose, raffinose, melezitose,
starch, glycogen, mannitol, sorbitol, inositol,
erythritol, esculin, salicin, or amygdalin.
Hydrolysis of starch: negative. esculin
positive.
Negative for: gas formation, indole
production, nitrate reduction, gelatin
liquefaction.
Diagnostic tablets/
disks Statens Serum
Institut Diagnostica,
Copenhagen,
Denmark, Rosco
Diagnostica, Taastrup,
Denmark
None. S. moorei strains produce relatively few
positive biochemical reactions. The
phenotypic identification of the isolates
were not able to produce uniform amount
of positive and negative reactions, the
isolates also differed from the ones
previously described.
Commercially
available tests
Fermentation of
carbohydrates and
enzyme tests
Vitek 2 ANC, BBL
Crystal Anaerobe,
RapID ANA II, API
ID32A
None. S. moorei cannot be identified using any
commercially available identification kits,
and report results as “no identification”
There are differences in results between
different commercial kits may be due to
different amounts of the substrate or
different reagents for detection.
MALDI-TOF MS Ribosomal protein
analysis
Vitek (bioMérieux) or
Bruker Matrix-
Assisted Laser
Desorption/Ionization
Time-of Flight
(MALDI-TOF)
Suitable, fast,
cheap, but
requires
expensive
instruments
and software.
Requires
continuous
software
updates.
The strains grow slowly and the organism
cannot be identified reliably by MALDI-
TOF. The organism's spectrum is
unavailable in the older databases.
16S rRNA gene
sequencing
DNA
sequencing is
necessary in
the process
of identifying
this
bacterium
from clinical
samples.
Only this method is considered truly
reliable.
diseases [58]. Ierardi et al. reported a possible relationship between hal-
itosis and Helicobacter pylori carriage in the stomach [15].
Years after its discovery, infections caused by S. moorei have been
seldom reported, and in these cases, the bacteria were mainly impli-
cated in different types of oral diseases: periodontal diseases, periim-
plantitis [33], dentoalveolar abscesses [36], subgingival plaques from
patients with refractory periodontitis [59], localized aggressive peri-
odontitis [60], halitosis [22, 64, 65], endodontic infections [14, 63],
peri-radicular lesions [35], infected root canals [34]. As of now, there
is insufficient evidence to suggest a role to S. moorei in the develop-
ment of dental caries [20]. Schirrmeister et al. [35] found that S. moorei
and F. nucleatum were the most common isolates in their study of n
= 10 periradicular infections; these organisms were each found in six
of the patients, and they were found in the same infections in five
of these cases. Some of these abovementioned studies showed that
S. moorei mostly resides in the oral region of patients experiencing
halitosis, whereas the detection frequency in healthy volunteers was
much lower. S. moorei adheres to oral epithelial cells through the use
of their adhesins and the subsequent formation of bacterial biofilm is
thought to be a key step in the development of halitosis [4]. In their
study Haraszthy et al. investigated the role of „non-culturable” bacte-
ria in halitosis: they have used direct amplification of 16S rDNA, to-
gether with traditional microbial culture methods to identify the oral
microbiome in the patients enrolled in the study. They found a greater
bacterial species-diversity in samples taken from the dorsal surface of
the tongue of subjects with halitosis: 32 species (13 “uncultured” or
“unidentified” species) in the halitosis group, while 17 species only in
the control group; S. moorei was considered a key, or „signal” bacterial
species among the species demonstrative of the halitosis group. In this
study, S. moorei was found in all halitosis subjects (100%), however, it
was not detected by either culture or direct amplification of bacterial
nucleid acid in the control subjects [61]. It is interesting to note that in
their study, only 14% of tested individuals without oral malodor were
positive for S. moorei, but all of these patients were experiencing peri
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odontitis [61]. In a previous study in 2003, Kazor et al. associated the
presence of halitosis with S. moorei, identifying it in only 1 out of 5 sub-
jects without halitosis and in 3 out of 6 subjects with halitosis [62]. Ac-
cording to Gonzales et al. who carried out a EuroPerio9 study in 2019,
S. moorei has the ability to generate VSCs in monospecies biofilms, al-
though at lower concentrations than F. nucleatum or P. gingivalis [64].
The participation of S. moorei in a biofilm fosters the presence of pig-
mented Prevotella and Porphyromonas species in the biofilm. This could
be explained by the β-galactosidase activity of S. moorei, which would
provide greater access to nutrients for proteolytic bacteria, such as
P. gingivalis or P. intermedia [24, 65]. Thus, S. moorei would facilitate
integration of VSC-producing bacteria in the biofilm, but on the other
hand, it is necessary to study the odor power of the VSCs that appeared
in biofilms with S. moorei to establish how closely associated they are
to bad breath [66]. In a study by Bernardi et al., culture-dependent
and independent methods were carried out to characterize the compo-
sition of the tongue biofilm of halitosis patients: in their report; their
study also highlighted the role of S. moorei (together with F. periodon-
tium, P. melaninogenica and T. forsythia) in halitosis [67].
4. Role of S. moorei in human infections, other than halitosis
Although S. moorei was mostly isolated from human feces and was
described as a member of the oral microbiota, this microorganism
should also be considered as an opportunistic pathogen, responsible for
severe infections. In addition to oral diseases, S. moorei has been re-
ported to cause various infections, although the reports concerning ex-
tra-oral infections are relatively rare [68]. Based on the currently pub-
lished reports, cases of infections caused by S. moorei mainly include
bloodstream and surgical wound infections. These infections were as-
sociated with different types of cancers, an immunosuppressed state
and some other predisposing factors, such are intravenous drug abuse,
thrombosis and other bacterial and viral infections [20]. There are only
eight different reports on bloodstream infection caused by S. moorei in
the literature (presented on a patient-by-patient basis in Table 2.). In-
terestingly, in many affected patients, the source of the infection was
presumed to be an abscess in the oral region. It has been suggested that
the VSC-production of halitosis-causing bacteria (high concentrations of
VSCs lead to increased permeability of the oral mucosa) The first case
of bloodstream infection was described by Detry et al. in 2006 from
a University Hospital in Belgium: the patient was a 67-year-old male
with multiple myeloma, when the source of infection was presumably
related to multiple dento-alveolar abscesses [69]. In a study concern-
ing anaerobic blood culture positivity between 2013 and 2017 (which
coincided with the introduction of MALDI-TOF MS in the routine diag-
nostic workflow of the laboratory) in a Southern Hungarian tertiary-care
hospital by Gajdács et al., out of the n = 423 strict anaerobic isolates,
four novel species were first reported in this geographical region [74].
All of the abovementioned novel species were among non-spore forming
Gram-positive anaerobes and in one case of a 58-year-old male patient,
S. moorei was the isolated pathogen. The improvements in the identifica-
tion of these non-spore forming Gram-positive bacteria may be attribut-
able to the developments in the MALDI databases, containing bacterial
spectra [75]. In another report from Hungary, Sárvári et al. described
five additional cases from the same region: all patients presented with
underlying diseases (malignancy in 4 out of the 5 cases), and in most
cases, S. moorei was isolated in mixed culture with other anaerobes of
facultative anaerobes [31].
Zheng et al. described nine cases (out of 400) of surgical wound in-
fections, when the complex aerobic-anaerobic bacterial culture involv-
ing the numerically dominant S. moorei flora played a principal role in
the development of the infections [24]. They found S. moorei and F. nu-
cleatum together in n = 2 of their cases, while S. moorei was found
with two other Fusobacterium species (namely F. equinum and F. gonidi
aformans) in one other case. They have hypothesized that S. moorei
and Fusobacterium strains may act synergistically (i.e. pathogenic syn-
ergy), and/or each may supply growth factors for one another in in vivo
conditions [24, 76]. Although the underlying mechanisms are not yet
fully understood, there are several examples for this kind of advanta-
geous interaction, e.g., between A. viscous and P. gingivalis (enhancing
eachothers’ growth and colonization levels in the oral cavity [77, 78])
and between F. nucleatum and T. forsythia (acting synergistically in pro-
tein degradation [79, 80]). A possible mechanism for in vivo synergism
between S. moorei and fusobacteria may be found in the initial steps of
VSC-production, where S. moorei is responsible for the initial deglycosy-
lation step, which is required for F. nucleatum subsequently degrade pro-
teins more effectively [81, 82].
5. Therapy of S. moorei infections, concluding remarks
In regards to the treatment of halitosis, the first step is the identifica-
tion of the extent and the origin of the malodor [83]. If the halitosis is
not pathological, adequate oral hygiene (including mechanical removal
of tongue biofilm with tongue scraping or with a toothbrush) and ab-
staining from the consumption of odorous compounds will resolve the
complaints [84]. Oral care may be supplemented by the use of prod-
ucts containing cetylpyridinium chloride, chlorhexidine, chloride diox-
ide, zinc salts or natural (plant-based) compounds capable of inhibiting
bacterial growth or neutralizing VSCs [85]. If halitosis is diagnosed to
be pathological, the management of the complaints will largely depend
on the origin (IOH or EOH), the organ systems affected and/or existing
underlying diseases of the patient [11].
S. moorei infections should be treated with antibiotic-therapy, taking
into account the anaerobic respiration of the pathogen [41]. Thus, only
agents with anti-anaerobic activity should be considered (penicillin,
piperacillin-tazobactam, clindamycin, metronidazole, meropenem, mox-
ifloxacin, tigecycline and vancomycin), in addition to the characteris-
tics of the patient (e.g., kidney function, hypersensitivity) and the clini-
cal presentation of the infection [86]. Based on the abovementioned re-
ports available, clinical S. moorei isolates exhibit uniform susceptibility
to common antibiotics used for the treatment anaerobic infections. In
dentistry, amoxicillin/clavulanic acid, metronidazole and clindamycin
are most frequently used: the former for its good tolerability, metronida-
zole for its potent anti-anaerobic activity (except for some Gram-positive
anaerobes, such as (Actinomyces spp., Bifidobacterium spp., Cutibacterium
spp. and Lactobacillus spp.)), while the latter is characterized by good
penetration into abscesses [87]. For dental infections and wound infec-
tions, surgical debridement and drainage of pus is commonly required
to supplement therapy and to oxygenize the affected tissues.
Solobacterium moorei is a recently described Gram-positive,
non-spore-forming, obligate anaerobic bacillus; this pathogen is less
well-known to clinicians as other members of Gram-positive rods. In
addition, the literature concerning these bacteria is extremely scarce,
which was demonstrated in this review. Regarding its pathogenic role,
the relevance of S. moorei in halitosis has a good standing, as it has
been suggested by multiple studies, while the isolation of these bac-
teria from invasive infections is very rare; there were only a few re-
ports of infections outside the oral cavity. Nevertheless, all of abovemen-
tioned articles point to the fact that S. moorei might be more prevalent
in bacteremia than believed so far, and the usefulness of MALDI-TOF MS
and 16S RNA gene sequencing for the discovery and identification of
this non-spore-forming strictly anaerobic Gram-positive bacillus (if these
technologies are available) cannot be emphasized enough times.
The clinical data available from the published reports indicate that
the patients to whom have compromised immunity (e.g., hematological
malignancies or solid tumors, diabetes, intravenous drug use and a sig-
nificant medical history previous surgical intervention) are more prone
to S. moorei bacteremia across all genders and age groups. Sepsis and/
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Table 2
Published cases of S. moorei bacteremia presented in a patient-by-patient basis.
Case
number Age/Sex Infection
Underlying
Diseases Output Treatment Author/Country Year
1. 67/M Sepsis
Dentoalveoral
abscess
Multiple
myeloma,
autologous bone
marrow graft
Improved
and
discharged
Cefepime
No surgical
Detry et al., [69]
Belgium
2006
2. 43/F Acute
proctitis
Carcinoma of
the cervix stage
III-B
Recovered Piperacillin-
tazobactam
No surgical
Lau et al., [27]
Hong-Kong
2006
3. 37/M Septic
pulmonary
embolism
femoral vein
Intravenous
drug abuse
Recovered penicillin and
metronidazole
No surgical
Martin et al. [70]
UK
2007
4. 43/M Fever,
anemia,
diarrhea,
Tooth abscess
Lymphoma,
kidney
transplantation
Recovered penicillin and
metronidazole
No surgical
Pedersen et al. [26]
Denmark
2011
5. 66/F Pulmonary
abscess,
Sepsis
Non-small-cell
lung carcinoma
with meningeal
carcinomatosis
Not
known
1. cefuroxime +
gentamicin
2: meropenem +
metronidazole +
ciprofloxacin
3.metronidazole
No surgical
6. 64/M Sepsis, fever Complicated
abdominal
surgery,
Colon cancer
Improved
and
discharged
Cefuroxime +
metronidazole
No surgical
7. 33/F Femoral vein
thrombosis
and abscess,
fever,
headache
Intravenous
drug abuse,
Chronic HBV
infection
Recovered 1.Cefuroxime
2.Penicillin +
metronidazole
No surgical
8. 77/M Pneumonia,
fever, dry
cough,
toothache
Prostate cancer
Previous
chronic heart
disease
Recovered Penicillin
No surgical
9. 56/M General
malaise
Fournier
gangreana
Not
known
Not known Hernandez Blaco et al. [71]
Spain
2017
10. 58/M Sepsis alcoholic
polyneuropathy,
encephalopathy,
COPD, broken
left femoral
neck and
neuromuscular
dysfunction of
the urinary
bladder
Died Did not accept any
antibiotics, intensive
or surgical therapy
Gajdács et al. [74]
Hungary
2017
11. 61/M Persistent
coma,
intermittent
convulsions,
halitosis,
intermittent
fever
TTC,
hypertension,
hyperlipidemia,
type 2 diabetes,
rectal cancer,
brucellosis
Died Vancomycin +
meropenem
No surgical
Liu et al. [72]
China
2019
12. 70/M Pneumonia HSV-1
oesophagitis,
HIV infection
Diabetes
Not
known
Amoxicillin/clavulanic
acid
Genderini et al. [73]
Belgium
2019
M: male; F: female; TTC: thrombotic thrombocytopenic purpura; HBV: hepatitis B virus; HIV: human immunodeficiency virus; HSV-1: herpes simplex virus-1.
or bacteremia caused by S. moorei may originate from different oral in-
fections, lung abscess, abdominal infections, and from the lesser-known
habit of licking needles by intravenous drug users. During clinical as-
sessment of patients with blood cultures positive for S. moorei, it is rec-
ommended to first search for dental focus of infection. Based on the
currently available reports, a case of possible pathogenic synergy be-
tween S. moorei and Fusobacterium spp. has been suggested (as they
have been commonly co-isolated), however, the exact mechanism is
poorly understood. Overall, it can be concluded that our present knowl
edge about S. moorei is scarce, and intense research associated to this
anaerobe is warranted to further characterize its role in the pathogene-
sis of human infections, including halitosis and invasive processes.
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